Table 4.
Patient | Proposed dose (mg) | |||||||
---|---|---|---|---|---|---|---|---|
Number | Dose (mg) | Referencea | ITSIM | Pmetrics | ||||
TAC OD D7 LSS 0,1 and 6 h |
1 | 4 | 4.5–6.0 | ↗ | 6.0–7.5 | ↗ | 8.0–10.0 | ↗ |
2 | 17 | 13.5–17.0 | = | 14.0–17.5 | = | 16.0–20.0 | = | |
3 | 18 | 14.0–17.5 | ↘ | 14.5–18.5 | = | 16.0–20.5 | = | |
4 | 15 | 11.5–14.0 | ↘ | 12.0–14.5 | ↘ | 13.0–16.0 | = | |
5 | 15 | 15.0–19.0 | = | 16.0–20.0 | ↗ | 15.5–19.0 | ↗ | |
6 | 23 | 9.5–12.0 | ↘ | 10.5–13.0 | ↘ | 9.5–11.0 | ↘ | |
7 | 3 | 6.5–8.5 | ↗ | 6.0–7.5 | ↗ | 6.0–7.5 | ↗ | |
8 | 23 | 17.0–21.0 | ↘ | 17.0–11.5 | ↘ | 16.0–20.0 | ↘ | |
9 | 6 | 7.0–9.0 | ↗ | 8.0–10.0 | ↗ | 8.0–10.0 | ↗ | |
10 | 15 | 10.5–13.0 | ↘ | 10.5–13.0 | ↘ | 10.0–12.5 | ↘ | |
TAC OD W6 LSS 0,1 and 6 h |
1 | 11 | 9.0–11.0 | = | 9.5–11.5 | = | 8.5–10.5 | ↘ |
2 | 22 | 18.0–23.0 | = | 19.0–24.0 | = | 16.0–20.0 | ↘ | |
3 | 15 | 9.0–11.5 | ↘ | 9.5–11.5 | ↘ | 8.5–11.0 | ↘ | |
4 | 20 | 10.0–12.0 | ↘ | 11.0–14.0 | ↘ | 11.5–14.5 | ↘ | |
5 | 25 | 15.5–19.5 | ↘ | 14.0–17.5 | ↘ | 13.5–17.0 | ↘ | |
6 | 12 | 8.0–10.0 | ↘ | 7.5–9.5 | ↘ | 8.5–11.0 | ↘ | |
7 | 19 | 11.5–14.0 | ↗ | 11.5–14.0 | ↘ | 11.0–14.0 | ↘ | |
8 | 6 | 4.0–5.0 | ↘ | 3.5–4.55 | ↘ | 4.0–4.5 | ↘ | |
9 | 25 | 10.5–13.0 | ↘ | 11.0–14.0 | ↘ | 11.0–14.0 | ↘ | |
10 | 8 | 6.0–7.5 | ↘ | 5.5–7.0 | ↘ | 6.0–7.5 | ↘ | |
TAC TD D7 LSS 0,2 and 6 h |
1 | 4 | 4.0–5.0 | = | 4.0–5.0 | = | 5.0–6.0 | ↗ |
2 | 13 | 9.0–11.5 | = | 10.0–12.5 | ↘ | 11.5–14.5 | = | |
3 | 16 | 7.0–9.0 | = | 7.5–9.0 | ↘ | 7.0–9.0 | ↘ | |
4 | 10 | 10.5–13.0 | ↗ | 9.5–12.0 | = | 10.5–13.0 | ↗ | |
5 | 14 | 23.5–29.5 | ↗ | 24.5–30.5 | ↗ | 17.0–21.5 | ↗ | |
6 | 10 | 11.0–13.5 | ↗ | 11.0–14.0 | ↗ | 9.5–12.0 | = | |
7 | 12 | 10.0–12.5 | = | 9.5–12.0 | = | 9.5–12.0 | = | |
8 | 14 | 7.5–9.0 | ↘ | 7.5–9.5 | ↘ | 8.5–10.5 | ↘ | |
9 | 11 | 6.0–7.0 | ↘ | 6.5–8.0 | ↘ | 7.0–8.5 | ↘ | |
10 | 18 | 15.0–19.0 | = | 16.5–21.0 | = | 18.0–22.5 | = | |
TAC TD W6 LSS 0, 1 and 3 h |
1 | 9.5 | 10–12.5 | ↗ | 9.0–11.5 | = | 10.0–12.5 | ↗ |
2 | 12 | 8.5–10.5 | ↘ | 8.0–10.0 | ↘ | 7.5–9.0 | ↘ | |
3 | 14 | 8.0–10.5 | ↘ | 8.5–10.5 | ↘ | 8.0–10.0 | ↘ | |
4 | 20 | 12.5–16.0 | ↘ | 11.0–14.0 | ↘ | 12.50–16.0 | ↘ | |
5 | 12 | 6.5–8.0 | ↘ | 6.5–8.0 | ↘ | 6.0–7.5 | ↘ | |
6 | 18 | 10.0–12.5 | ↘ | 10.0–12.5 | ↘ | 8.5–11.0 | ↘ | |
7 | 24 | 16.0–20.0 | ↘ | 16.5–21.0 | ↘ | 14.0–17.5 | ↘ | |
8 | 10 | 5.5–6.5 | ↘ | 5.5–7.0 | ↘ | 5.0–6.5 | ↘ | |
9 | 12 | 5.0–6.5 | ↘ | 5.5–7.0 | ↘ | 7.0–8.5 | ↘ | |
10 | 14 | 10.5–13.0 | ↘ | 10.5–13.3 | ↘ | 9.0–11.5 | ↘ |
Reference, Trapezoidal method: proposed dose derived from the trapezoidal AUC0–12 h for TD and AUC0–24 h for OD; Poorly estimated doses are in bold characters; D7, day 7; OD, Advagraf; TAC, tacrolimus; TD, Prograf; W6, week 6.